The insider selling is negligible relative to market cap and carries no informational signal. Monitor for any material corporate events (earnings, M&A, regulatory decisions) that could explain the sales, but no immediate action warranted.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $128.42entry
- T+1 · 6mo ago +1.33%α +1.19% · $130.13
- T+5 · 5mo ago −2.19%α +0.56% · $125.61
- T+20 · 5mo ago +19.71%α +22.03% · $153.74
- T+60 · 3mo ago +28.42%α +27.45% · $164.92
Price Chart
How similar events traded
Executive Summary
Three Guardant Health insiders, including the Chief Legal Officer and Chief Commercial Officer, sold a total of $4.28M in open-market sales over a 7-day window. The CCO's $2.9M sale is the largest, representing about 0.024% of the $17.7B market cap, which is trivial. The cluster is entirely sells with no buys, but the dollar amounts are immaterial relative to company size, and the sales are likely liquidity-driven or part of routine 10b5-1 plans.
Key Financial Metrics
Key Facts
- Three insiders sold a total of $4.28M in open-market sales from May 22-28, 2026.
- Chief Commercial Officer Chris Freeman sold 24,400 shares for $2.90M at $118.67.
- Chief Legal Officer John Saia sold 9,994 shares for $1.25M at $125.08.
- Director Manuel Hidalgo Medina sold 1,000 shares for $130K at $130.06.
- Total sales represent ~0.024% of Guardant Health's $17.7B market cap.
- No insider purchases were reported in the cluster.
Financial Impact
Total insider sales of $4.28M, representing ~0.024% of market cap, immaterial.
Risk Factors
- Insider sales could be misinterpreted as bearish by retail traders despite being immaterial.
- If the CCO's sale is part of a 10b5-1 plan, it is non-informative; if not, it may reflect personal liquidity needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-GH-1780090262229 |
Track record
38 reports on GH
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.49% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $145.04 Now $144.03 −0.70% settles Dec 16
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $150.87 Now $144.03 −4.53% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $153.43 Now $144.03 −6.13% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $168.58 Now $144.03 −14.56% settles Dec 3
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $175.00 Now $144.03 −17.70% settles Dec 2
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $162.94 Now $144.03 −11.61% settles Nov 19
- Oct 14, 20264w ago 144 Neutral 2/10 Entry $165.88 to $154.86 Now $144.03 −13.17% ▼ −6.64% −4.74% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 5/10 Entry $179.38 to $158.60 Now $144.03 +19.71% ▲ +11.58% +11.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers